New combo therapy aims to shrink rectal tumors and avoid surgery
NCT ID NCT07175636
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tests a new approach for people with locally advanced rectal cancer that is not responsive to immunotherapy alone. Participants first receive short-course radiation, then a combination of an experimental immunotherapy drug (QL1706) and chemotherapy. The goal is to shrink or eliminate the tumor before any planned surgery, potentially allowing some patients to avoid surgery altogether. About 66 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.